Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AORT Artivion	$32.11 +0.2%	$30.44	$21.97 ▼ $32.94	$1.37B	1.64	313,501 shs	196,103 shs
CDRE Cadre	$34.74 +5.0%	$33.19	$27.07 ▼ $40.28	$1.34B	1.31	229,584 shs	400,445 shs
DCTH Delcath Systems	$10.52 -6.7%	$13.33	$7.17 ▼ $18.23	$392.49M	0.82	711,743 shs	1.44 million shs
ENOV Enovis	$26.41 -0.8%	$30.80	$25.47 ▼ $49.83	$1.52B	1.7	1.61 million shs	975,152 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AORT Artivion	+0.17%	+1.88%	+4.53%	+13.31%	+28.45%
CDRE Cadre	+4.99%	+4.29%	+7.82%	-1.79%	+5.62%
DCTH Delcath Systems	-6.65%	-3.57%	-17.33%	-9.39%	+26.44%
ENOV Enovis	-0.73%	-3.44%	-21.52%	-22.70%	-36.70%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AORT Artivion	2.3482 of 5 stars	1.6	4.0	0.0	2.6	2.5	1.9
CDRE Cadre	2.2792 of 5 stars	1.3	1.0	2.5	3.0	3.3	1.9
DCTH Delcath Systems	2.8545 of 5 stars	3.5	2.0	0.0	3.1	2.5	0.6
ENOV Enovis	2.9349 of 5 stars	3.4	3.0	0.0	1.0	1.7	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AORT Artivion	3.17	Buy	$32.40	0.89% Upside
CDRE Cadre	2.50	Moderate Buy	$37.50	7.94% Upside
DCTH Delcath Systems	3.00	Buy	$24.00	128.14% Upside
ENOV Enovis	2.80	Moderate Buy	$55.60	110.53% Upside

Current Analyst Ratings Breakdown

Latest DCTH, ENOV, AORT, and CDRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	ENOV Enovis	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$48.00 ➝ $46.00
6/23/2025	DCTH Delcath Systems	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$25.00
6/17/2025	AORT Artivion	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$35.00
6/13/2025	CDRE Cadre	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$45.00 ➝ $38.00
5/23/2025	DCTH Delcath Systems	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $29.00
5/14/2025	ENOV Enovis	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$75.00 ➝ $70.00
5/9/2025	ENOV Enovis	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$62.00 ➝ $55.00
5/9/2025	ENOV Enovis	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$64.00 ➝ $57.00
5/6/2025	AORT Artivion	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/6/2025	AORT Artivion	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$33.00 ➝ $33.00
5/6/2025	AORT Artivion	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00

(Data available from 8/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AORT Artivion	$388.54M	3.53	$0.84 per share	38.43	$6.59 per share	4.87
CDRE Cadre	$567.56M	2.49	$1.49 per share	23.35	$7.67 per share	4.53
DCTH Delcath Systems	$37.21M	9.85	N/A	N/A	$2.15 per share	4.89
ENOV Enovis	$2.11B	0.72	$19.00 per share	1.39	$45.10 per share	0.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AORT Artivion	-$13.36M	-$0.50	N/A	64.23	N/A	-5.49%	3.63%	1.34%	8/7/2025 (Estimated)
CDRE Cadre	$36.13M	$0.95	36.57	25.54	1.22	6.87%	12.52%	6.04%	N/A
DCTH Delcath Systems	-$26.39M	-$0.50	N/A	N/A	N/A	-26.38%	-29.44%	-20.75%	8/6/2025 (Estimated)
ENOV Enovis	-$825.49M	-$13.95	N/A	8.28	N/A	-37.65%	5.99%	3.44%	8/7/2025 (Estimated)

Latest DCTH, ENOV, AORT, and CDRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	AORT Artivion	$0.11	N/A	N/A	N/A	$107.96 million	N/A
8/7/2025	Q2 2025	ENOV Enovis	$0.74	N/A	N/A	N/A	$555.80 million	N/A
8/6/2025	Q2 2025	DCTH Delcath Systems	$0.02	N/A	N/A	N/A	$22.84 million	N/A
8/5/2025	Q2 2025	CDRE Cadre	$0.25	$0.30	+$0.05	$0.30	$153.23 million	$157.11 million
5/8/2025	Q1 2025	DCTH Delcath Systems	$0.10	$0.03	-$0.07	$0.03	$16.83 million	$19.80 million
5/8/2025	Q1 2025	ENOV Enovis	$0.74	$0.81	+$0.07	-$0.98	$558.80 million	$558.83 million
5/6/2025	Q1 2025	CDRE Cadre	$0.13	$0.23	+$0.10	$0.23	$121.53 million	$130.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AORT Artivion	N/A	N/A	N/A	N/A	N/A
CDRE Cadre	$0.38	1.09%	N/A	40.00%	2 Years
DCTH Delcath Systems	N/A	N/A	N/A	N/A	N/A
ENOV Enovis	N/A	N/A	N/A	N/A	N/A

Latest DCTH, ENOV, AORT, and CDRE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/22/2025	CDRE Cadre	quarterly	$0.0950	1.16%	8/1/2025	8/1/2025	8/15/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AORT Artivion	1.08	5.53	3.95
CDRE Cadre	0.66	3.55	2.57
DCTH Delcath Systems	N/A	15.95	14.61
ENOV Enovis	0.52	2.55	1.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AORT Artivion	86.37%
CDRE Cadre	43.95%
DCTH Delcath Systems	61.12%
ENOV Enovis	98.45%

Insider Ownership

Company	Insider Ownership
AORT Artivion	8.10%
CDRE Cadre	37.00%
DCTH Delcath Systems	17.94%
ENOV Enovis	2.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AORT Artivion	1,600	42.70 million	39.24 million	Optionable
CDRE Cadre	2,284	40.66 million	25.62 million	Optionable
DCTH Delcath Systems	60	34.83 million	28.58 million	Optionable
ENOV Enovis	7,367	57.12 million	55.58 million	Optionable

DCTH, ENOV, AORT, and CDRE Headlines

Recent News About These Companies

Enovis Earnings: What To Look For From ENOV

5 hours ago | finance.yahoo.com

Indiana surgeon completes state’s 1st augmented reality shoulder replacement

August 4 at 2:51 PM | beckersspine.comB

Enovis (NYSE:ENOV) Reaches New 12-Month Low - What's Next?

August 2, 2025 | marketbeat.com

Enovis (ENOV) Expected to Announce Quarterly Earnings on Thursday

July 31, 2025 | americanbankingnews.com

Enovis (ENOV) Projected to Post Earnings on Thursday

July 31, 2025 | marketbeat.com

3 Reasons to Sell ENOV and 1 Stock to Buy Instead

July 28, 2025 | msn.com

11,889 Shares in Enovis Corporation (NYSE:ENOV) Acquired by First National Advisers LLC

July 28, 2025 | marketbeat.com

Royce & Associates LP Acquires 20,230 Shares of Enovis Corporation (NYSE:ENOV)

July 25, 2025 | marketbeat.com

Oak Thistle LLC Grows Holdings in Enovis Corporation (NYSE:ENOV)

July 25, 2025 | marketbeat.com

Victory Capital Management Inc. Has $10.51 Million Holdings in Enovis Corporation (NYSE:ENOV)

July 25, 2025 | marketbeat.com

Enovis Corporation (NYSE:ENOV) Holdings Decreased by Diamond Hill Capital Management Inc.

July 24, 2025 | marketbeat.com

Enovis Corporation (NYSE:ENOV) Shares Sold by Mutual of America Capital Management LLC

July 24, 2025 | marketbeat.com

Enovis (ENOV) Stock Trades Up, Here Is Why

July 23, 2025 | finance.yahoo.com

Homestead Advisers Corp Grows Stake in Enovis Corporation (NYSE:ENOV)

July 22, 2025 | marketbeat.com

Enovis (NYSE:ENOV) Sets New 52-Week Low - Should You Sell?

July 19, 2025 | marketbeat.com

Louisiana State Employees Retirement System Buys 11,300 Shares of Enovis Corporation (NYSE:ENOV)

July 19, 2025 | marketbeat.com

Bernzott Capital Advisors Grows Position in Enovis Corporation (NYSE:ENOV)

July 18, 2025 | marketbeat.com

Enovis stock ticks down after Jehoshaphat Research reveals short position

July 17, 2025 | investing.com

Enovis Corporation (NYSE:ENOV) Shares Acquired by Tributary Capital Management LLC

July 17, 2025 | marketbeat.com

Evercore ISI Maintains a Buy on Enovis Corporation (ENOV) With a $46 PT

July 16, 2025 | insidermonkey.com

As Austin aims to attract more life sciences companies, this suburb vies to be a hub for the sector

July 15, 2025 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
America Wants Drone Dominance: Are These Stocks Ready to Soar?
By Chris Markoch | July 20, 2025
View America Wants Drone Dominance: Are These Stocks Ready to Soar?
Super Micro Computer Sees Unusual Volume—Catalyst Ahead?
By Gabriel Osorio-Mazilli | July 25, 2025
View Super Micro Computer Sees Unusual Volume—Catalyst Ahead?
This Drone Stock Is on Sale Despite Big Army Contract
By Jeffrey Neal Johnson | July 31, 2025
View This Drone Stock Is on Sale Despite Big Army Contract
Enovix Shares Hit 6-Month High; Long-Term Highs to Follow
By Thomas Hughes | July 10, 2025
View Enovix Shares Hit 6-Month High; Long-Term Highs to Follow

DCTH, ENOV, AORT, and CDRE Company Descriptions

Artivion NYSE:AORT

$32.11 +0.05 (+0.17%)

Closing price 08/5/2025 03:59 PM Eastern

Extended Trading

$32.83 +0.71 (+2.22%)

As of 07:43 AM Eastern

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.

Cadre NYSE:CDRE

$34.74 +1.67 (+5.05%)

Closing price 08/5/2025 03:59 PM Eastern

Extended Trading

$32.51 -2.23 (-6.42%)

As of 08:00 AM Eastern

Cadre Holdings, Inc. manufactures and distributes safety that provides protection to users in hazardous or life-threatening situations in the United States and internationally. The company operates in two segments, Products and Distribution. It offers body armor product, such as concealable, corrections, and tactical armor under the Safariland and Protech Tactical brand names; survival suits, remotely operated vehicles, specialty tools, blast sensors, accessories, and vehicle blast attenuation seats for bomb safety technicians; bomb suits; duty gear, including belts and accessories; and other protective equipment comprising communications gear, forensic and investigation products, firearms cleaning solutions, and crowd control products. The company also offers third-party products, such as uniforms, optics, boots, firearms, and ammunition. It serves first responders, such as state and local law enforcement, fire and rescue, explosive ordnance disposal technicians, emergency medical technicians, fishing, and wildlife enforcement and departments of corrections, as well as federal agencies including the U.S. Department of State, U.S. Department of Defense, U.S. Department of Interior, U.S. Department of Justice, U.S. Department of Homeland Security, U.S. Department of Corrections, the Department of Energy, Los Alamos National Laboratories, Waste Isolation Plant, and various foreign government agencies. Cadre Holdings, Inc. was founded in 1964 and is headquartered in Jacksonville, Florida.

Delcath Systems NASDAQ:DCTH

$10.52 -0.75 (-6.65%)

Closing price 08/5/2025 04:00 PM Eastern

Extended Trading

$11.58 +1.06 (+10.03%)

As of 08:17 AM Eastern

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.

Enovis NYSE:ENOV

$26.41 -0.22 (-0.83%)

Closing price 08/5/2025 03:59 PM Eastern

Extended Trading

$26.74 +0.32 (+1.23%)

As of 08:00 AM Eastern

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time